Arena Pharmaceuticals Rating Increased to Outperform at Leerink Swann (ARNA)

By admin | 6 years ago

Arena Pharmaceuticals (NASDAQ: ARNA) was upgraded by research analysts at Leerink Swann from a “market perform” rating to an “outperform” rating in a report released on Friday.

Shares of Arena Pharmaceuticals traded up 3.93% during mid-day trading on Friday, hitting $6.61. Arena Pharmaceuticals has a one year low of $1.23 and a one year high of $3.47. The company’s market cap is $1.206 billion.

Several other analysts have also recently commented on the stock. Analysts at Jefferies Group (NYSE: JEF) upgraded shares of Arena Pharmaceuticals from an “underperform” rating to a “buy” rating in a research note to investors on Friday. They now have a $1.00 price target on the stock, down previously from $9.00. Separately, analysts at BMO Capital Markets upgraded shares of Arena Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note to investors on Wednesday, May 9th. Finally, analysts at Piper Jaffray (NYSE: PJC) downgraded shares of Arena Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note to investors on Wednesday, March 28th. They now have a $2.50 price target on the stock.

Arena Pharmaceuticals, Inc. (Arena) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors (GPCRs), in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.

About the author